Division of PharmaMar SA/Zeltia SA
Latest From Sylentis SA
ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.
Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
- Contact Info
C/Santiago Grisolia 2
Tres Cantos, 28760
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.